Paul Mischel, M.D.

Edit your Faculty Profile

A Short Biography:

The Mischel laboratory aims to transform the care of patients with glioblastoma, the most common form of brain cancer in adults, through molecular medicine. The Mischel laboratory has developed quantitative molecular approaches to study and understand the signaling networks that are altered in brain cancer and begun to use these approaches to develop more effective, less toxic, treatments for patients. Their work has illuminated critical molecular determinants of response to EGFR/PI3K/mTOR targeted therapies. The Mischel laboratory has also begun to elucidate the molecular circuitry by which altered EGFR/PI3K signaling in glioblastoma changes rewires tumor cell metabolism in a potentially targetable fashion. Through collaborations with Jim Heath?s group at CalTech as part of the NanoSystems Biology Cancer Center, the Mischel group is developing powerful new state-of-the-art molecular diagnostics to guide improved personalized treatment for brain cancer patients.
Work Titles
Education:
Degrees:
M.D., Cornell University Medical College, 1991
Fellowship:
1996 - 1998 Howard Hughes Medical Institute
1993 - 1995 UCLA School of Medicine
Internship:
1991 - 1992 UCLA Neuropsychiatric Hospital
Residency:
1992 - 1996 UCLA School of Medicine
Certifications:
Certifications:
1997 American Board of Pathology

Contact Information:

Detailed Biography:

Dr. Paul Mischel is the Lya and Harrison Latta Professor of Pathology and Laboratory Medicine and holds a joint appointment in the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. Dr. Mischel graduated Alpha Omega Alpha with an M.D. from Cornell University Medical College and trained in Anatomic Pathology and Neuropathology at UCLA. Dr. Mischel obtained his post-doctoral research training in the laboratory of Dr. Louis F. Reichardt at the Howard Hughes Medical Institute at UCSF and joined the UCLA faculty in 1998. Dr. Mischel has received a number of awards, including the Farber Award in 2007, the top brain tumor research award given jointly by the Society for Neuro-Oncology and the American Association of Neurosurgery. Dr. Mischel's work was profiled by the Journal of Cell Biology in June 2008. Dr. Mischel was inducted into the American Society for Clinical Investigation (ASCI) in 2007 and was elected to serve on their council. Dr. Mischel is currently the President-elect of the ASCI. Expertise: Dr. Mischel is a board certified neuropathologist with expertise in signal transduction biology. His laboratory focuses on the development and application of molecularly targeted therapies for glioblastoma and on the application of emerging technologies to identify the patients most likely to benefit from these new treatments.
Please visit the Mischel Lab Click here:

Visit the UCLA Pathology Site here: Pathology

Visit the Jonnson Cancer Center here: JCCC

Visit UCLA Molecular & Medical Pharmacology Site here: Pharmacology

Visit the UCLA ACCESS Faculty page here: ACCESS

Does this profile need updating? Contact Us